首页> 外文期刊>Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists >Pre-operative ultrasound identification of thyroiditis helps predict the need for thyroid hormone replacement after thyroid lobectomy
【24h】

Pre-operative ultrasound identification of thyroiditis helps predict the need for thyroid hormone replacement after thyroid lobectomy

机译:甲状腺炎的术前超声检查有助于预测甲状腺叶切除术后是否需要更换甲状腺激素

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: To evaluate whether pre-operative thyroiditis identified by ultrasound (US) could help predict the need for thyroid hormone replacement (THR) following thyroid lobectomy.Methods: Data from patients who underwent thyroid lobectomy in 2006-2011, were not taking THR pre-operatively, and had ≥1 month of follow-up were reviewed retrospectively. THR was prescribed for relatively elevated thyroid-stimulating hormone (TSH) and hypothyroid symptoms. The Kaplan-Meier method was used to estimate the percentage of patients who required THR at 6, 12, 18, and 24 months postoperatively, and Cox proportional hazards regression models were used to evaluate prognostic factors for requiring post-thyroid lobectomy THR.Results: During follow-up, 45 of 98 patients required THR. Median follow-up among patients not requiring THR was 11.6 months (range, 1.2 to 51.3 months). Six months after thyroid lobectomy, 22% of patients were taking THR (95% confidence interval [CI], 15-32%); the proportion increased to 46% at 12 months (95% CI, 36-57%) and 55% at 18 months (95% CI, 43-67%). On univariate analysis, significant prognostic factors for postoperative THR included a pre-operative TSH level >2.5 μ international units [IU]/mL (hazard ratio [HR], 2.8; 95% CI, 1.4-5.5; P = .004) and pathology-identified thyroiditis (HR, 2.4; 95% CI, 1.3-4.3; P = .005). Patients with both pre-operative TSH >2.5 μIU/mL and US-identified thyroiditis had a 5.8-fold increased risk of requiring postoperative THR (95% CI, 2.4-13.9; P<.0001).Conclusion: A pre-operative TSH level >2.5 μIU/mL significantly increases the risk of requiring THR after thyroid lobectomy. Thyroiditis can add to that prediction and guide pre-operative patient counseling and surgical decision making. US-identified thyroiditis should be reported and post-thyroid lobectomy patients followed long-term (≥18 months).
机译:目的:评估超声(美国)确定的术前甲状腺炎是否可以帮助预测甲状腺叶切除术后甲状腺激素替代(THR)的必要性。方法:2006-2011年未进行THR的甲状腺叶切除患者的数据-手术,并进行了≥1个月的随访。规定THR用于相对较高的甲状腺刺激激素(TSH)和甲状腺功能减退症状。使用Kaplan-Meier方法评估术后6、12、18和24个月需要THR的患者百分比,并使用Cox比例风险回归模型评估需要进行甲状腺叶切除THR的预后因素。在随访期间,98名患者中有45名需要THR。不需要THR的患者中位随访时间为11.6个月(范围1.2至51.3个月)。甲状腺叶切除术后六个月,有22%的患者正在服用THR(95%的置信区间[CI],15-32%);该比例在12个月时增加到46%(95%CI,36-57%),在18个月时增加55%(95%CI,43-67%)。在单因素分析中,术后THR的重要预后因素包括术前TSH水平> 2.5μ国际单位[IU] / mL(危险比[HR],2.8; 95%CI,1.4-5.5; P = .004)和病理学确定的甲状腺炎(HR,2.4; 95%CI,1.3-4.3; P = 0.005)。术前TSH> 2.5μIU/ mL且美国确定的甲状腺炎患者需要术后THR的风险增加5.8倍(95%CI,2.4-13.9; P <.0001)。结论:术前TSH浓度> 2.5μIU/ mL会显着增加甲状腺叶切除术后需要THR的风险。甲状腺炎可以增加这一预测,并指导术前患者咨询和手术决策。应报告美国确定的甲状腺炎,并且对甲状腺叶切除术后的患者进行长期随访(≥18个月)。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号